Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018; Revises Revenue Guidance for the Year 2018
The ongoing 2018 business performance achieved to 30 September allows the Board to reaffirm full-year 2018 guidance of 35% to 40% revenue growth to AUD 26 million to AUD 27 million, over initial revenue 2018 guidance of AUD 25 million to AUD 26 million.